)
Iovance Biotherapeutics (IOVA) investor relations material
Iovance Biotherapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial launch and market opportunity
Q3 2026 sales reached $122M for AMTAGVI and PROLEUKIN; FY 2025 sales were $264M, and 9M 2026 revenue was $292M.
ATC expansion remains a priority; at least 110 centers are targeted by year-end 2026, with management on track to meet or exceed that goal.
U.S. second-line-plus metastatic melanoma represents ~8,500 patients; first-line melanoma exceeds 22,000, while non-squamous lung market potential is 7x melanoma’s.
AMTAGVI is approved in the U.S., Canada and Australia; Switzerland and U.K. approvals are expected in Q1 2027, with an EU resubmission planned.
Philadelphia manufacturing can scale through existing modular capacity; cryopreserved product has a 12-month shelf life, and new facilities are not in immediate plans.
Financial outlook and operations
FY 2026 revenue guidance is $410M–$420M; management said it feels in good shape and expects continued growth from treating more patients.
Q3 gross margin was 60%, with 9M margin at 54%; long-term goal remains 70% or higher, without a specified timeframe.
Cost control and plant efficiencies are supporting margin improvement; quarterly results may vary, while management expects longer-term progress.
January 1, 2027 price increases: 9% for AMTAGVI and 7% for PROLEUKIN; reported cash balance was $382M at the end of the last reported quarter.
Prior plant upgrades are expected to prevent routine maintenance from disrupting production; clinical trials and operating expenses are being managed with financial discipline.
Melanoma development
Phase III TILVANCE-301 serves as the U.S. accelerated-approval confirmatory trial and supports potential first-line accelerated and eventual confirmatory approvals; enrollment is well underway.
Recent first-line phase II data showed an ORR above 60% and a notably high complete-response rate; final data cut is complete and a manuscript is in preparation.
Management plans to share more melanoma data; second-line patients treated with two or fewer prior lines had response rates above 50%, and five-year data showed median overall survival exceeding 36 months.
- Record Q3 revenue and ~60% gross margin as Amtagvi adoption and registrational trials advanced.IOVA
Q3 2026 - Durable melanoma responses anchor a growing solid-tumor TIL pipeline.IOVA
Corporate presentation - Lifileucel achieved a 59.1% ORR in the biomarker-enriched mNSCLC subgroup.IOVA
Study update - Record revenue and strong clinical results drive expansion and innovation in TIL therapy.IOVA
H.C. Wainwright 28th Annual Global Investment Conference - Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook.IOVA
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue surged 66% to $99.3M, margin hit 56%, and cash reserves support ongoing growth.IOVA
Q2 2026 - Strong revenue growth and durable TIL therapy efficacy drive expansion in solid tumor oncology.IOVA
Corporate presentation - Five-year data confirm durable survival and expanding access for one-time TIL cell therapy in melanoma.IOVA
KOL event - Q1 2025 revenue was $49.3M; FY25 guidance is $250–$300M with global expansion underway.IOVA
Q1 2025
)
)
)
)
)
)
)
)